[Ip-health] NY Times editorial: No Justification for High Drug Prices

Peter Maybarduk pmaybarduk at citizen.org
Sun Dec 20 07:58:58 PST 2015

On the other hand those are "discounts"  off prices the companies themselves set, often in a competition-free environment, having gamed out the prices they will offer various payers in advance. They aren't discounts so much as they are simply varying prices in a profit maximization strategy. 

-----Original Message-----
From: Peter Pitts [mailto:ppitts at cmpi.org] 
Sent: Sunday, December 20, 2015 9:25 PM
To: ip-health
Cc: Peter Maybarduk
Subject: Re: [Ip-health] NY Times editorial: No Justification for High Drug Prices

The editorial "No Justification for High Drug Prices" (NYT, 12/20/15) quotes the "list" price for  innovative medicines from Eli Lilly (Portazza for lung cancer)) and Pfizer (Ibrance for advanced breast cancer). The prices mentioned are true, but the context is inaccurate. Most every innovative new medicine offers significant discounts to private insurance payers (generally between 35-50%) in addition to double digit rebates for Medicare and Medicaid. There are very few patient paying "list price" and for those without insurance both of these companies (and mostly all innovative pharmaceutical developers) offer programs that provide their products at low or no cost. Context matter and accuracy counts.

Peter J. Pitts, a former FDA Associate Commissioner, is President of the Center for Medicine in the Public Interest On Dec 20, 2015, at 9:36 AM, Peter Maybarduk wrote:

> http://www.nytimes.com/2015/12/20/opinion/sunday/no-justification-for-
> high-drug-prices.html?action=click&pgtype=Homepage&clickSource=story-h
> eading&module=opinion-c-col-left-region&region=opinion-c-col-left-regi
> on&WT.nav=opinion-c-col-left-region&_r=0
> By the Editorial Board / Dec. 19
> There is ample evidence that drug prices have been pushed to astronomical heights for no reason other than the desire of drug makers to maximize profits. Prices in many cases far exceed what's needed to cover the costs of research and clinical trials, and some companies have found ways to rake in profits even without shouldering the cost of drug development.
> The two worst offenders are bottom feeders that simply buy companies they believe have underpriced their drugs and then quickly raise prices to astronomical levels.
> In August, Turing Pharmaceuticals acquired the American marketing 
> rights to a 62-year-old drug to treat a devastating parasitic infection andraised the cost of one pill to $750 from $13.50. That brought the cost of a course of treatment for some patients to hundreds of thousands of dollars. (Turing's founder, Martin Shkreli, was indicted on Thursday on charges of securities fraud involving a hedge fund and another biotechnology firm he started.) Valeant Pharmaceuticals greatly increased the prices of several drugs it acquired, including two used by hospitals to treat heart conditions. It also protected its high-priced dermatology drugs by urging doctors to send prescriptions to a mail-order pharmacy that would make sure no cheaper alternative was substituted.
> The Pharmaceutical Research and Manufacturers of America, a trade group, described Turing and Valeant as essentially investment vehicles "masquerading as pharmaceutical companies."
> Yet even some mainstream companies have set high prices that seem hard to justify. Eli Lilly said its new lung cancer drug, Portrazza, would cost about $11,430 a month in the United States, six times the $1,870 price that leading oncologists said in a recent journal article would be a fair reflection of the benefit the drug offers compared with older therapies.
> Similarly, Pfizer set the list price for Ibrance, a drug to treat a form of advanced breast cancer, at $9,850 a month, a price that remains high even after the 20 percent discount demanded by insurers. The price was not based on manufacturing costs or research costs, according to an analysis by The Wall Street Journal. Rather, Pfizer set the price as high as it could without causing doctors and insurers to favor an alternative drug.
> The pharmaceutical industry often defends its prices by noting that drugs account for only 10 percent of nationwide health spending. But in employer-based health insurance plans, drug benefits account for 19 percent of spending, not much less than spending on inpatient hospital care, according to a recent analysis by the Kaiser Family Foundation. And surveys have shown that many Americans have difficulty paying for the drugs they need. Major drug companies often increase prices 10 percent or more a year, far faster than inflation, straining the health care system.
> Experts have proposed several ways to reduce drug prices, like fostering greater competition among drug companies or allowing the government to negotiate lower prices. Encouraging the development of innovative drugs and setting prices in ways that make lifesaving medicines affordable to all are not mutually exclusive ideas.
> _______________________________________________
> Ip-health mailing list
> Ip-health at lists.keionline.org
> http://lists.keionline.org/mailman/listinfo/ip-health_lists.keionline.
> org

More information about the Ip-health mailing list